This is the authors' abstract. We don't add key points for this paper.
Case studies of nodal immune flares after neoadjuvant durvalumab (A) and durvalumab+tremelimumab (B) therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: